What is the appropriate acute and chronic management for a patient presenting with a regular narrow‑complex supraventricular tachycardia?

SVT Management

For acute management of regular narrow-complex SVT, start with vagal maneuvers immediately, followed by adenosine 6 mg IV rapid push if vagal maneuvers fail—this terminates 90-95% of cases. If the patient is hemodynamically unstable at any point, proceed directly to synchronized cardioversion.

Acute Management Algorithm

Step 1: Assess Hemodynamic Stability

• Unstable (hypotension, altered mental status, shock, chest pain, acute heart failure): Proceed immediately to synchronized cardioversion 1
• Stable: Continue to Step 2

Step 2: Vagal Maneuvers (First-Line)

Perform vagal maneuvers with patient supine 1:

• Valsalva maneuver: Bear down against closed glottis for 10-30 seconds (30-40 mmHg pressure)
• Carotid sinus massage: Apply steady pressure for 5-10 seconds after confirming no bruit
• Ice-cold towel to face: Alternative diving reflex maneuver
• Success rate: ~28% when switching between techniques 1

Critical pitfall: Never apply pressure to eyeballs—this is dangerous and abandoned 1

Step 3: Adenosine (Drug of Choice)

If vagal maneuvers fail, give adenosine 2, 1:

• Dose: 6 mg IV rapid push, followed by 20 mL saline flush
• Success rate: 90-95% for AVNRT/AVRT 1
• Dual purpose: Terminates tachycardia AND diagnostic (unmasks atrial activity if AT or flutter)
• Have cardioversion available—adenosine can precipitate atrial fibrillation with rapid ventricular response 1

Step 4: Alternative IV Medications (If Adenosine Fails)

For hemodynamically stable patients 1:

Preferred options (Class IIa):

• IV diltiazem or verapamil: 64-98% conversion rate
  • Give slowly over 20 minutes to minimize hypotension 1
  • Contraindications: Suspected VT, pre-excited AF, systolic heart failure

Reasonable alternative:

• IV beta-blockers (esmolol, metoprolol): Less effective than calcium channel blockers but excellent safety profile 1

Important downgrade from 2003 guidelines: Amiodarone and digoxin are no longer recommended for acute narrow-complex SVT 2

Step 5: Cardioversion

If medications fail or are contraindicated, perform synchronized cardioversion 1:

• Success rate: 80-98% for SVT termination
• Use sedation/anesthesia in stable patients
• Watch for premature complexes post-cardioversion that may reinitiate tachycardia

Chronic Management

Decision Framework

All patients should be referred to cardiac electrophysiology for specialist evaluation 3. Management depends on:

• Frequency and duration of episodes
• Symptom severity
• Patient preference
• Risk stratification

Treatment Options

1. Catheter Ablation (Preferred for Symptomatic Patients)

• Success rate: 95%
• Recurrence rate: <5%
• Heart block risk: <1%
• Curative therapy—should be strongly considered for symptomatic patients 4

2. Oral Medications (For Those Declining Ablation) 1:

First-line chronic therapy:

• Verapamil or diltiazem (Class I recommendation)
• Beta-blockers (metoprolol, atenolol)
• Well-tolerated, effective alternatives to ablation
• Avoid in systolic heart failure

Second-line options (Class Ic antiarrhythmics):

• Flecainide or propafenone
• Use only after structural heart disease excluded

Important changes from older guidelines: The 2019 ESC guidelines downgraded or removed many previously used agents 2:

• Amiodarone, sotalol: No longer recommended for chronic AVNRT
• "Pill-in-the-pocket" approach: No longer recommended
• Class Ia drugs (quinidine, procainamide, disopyramide): Removed due to modest effectiveness and adverse effects

Critical Caveats

Pre-Excited SVT (Wolff-Parkinson-White)

If you see wide-complex irregular tachycardia suggesting pre-excited AF:

• Never give adenosine, diltiazem, verapamil, or beta-blockers—can cause ventricular fibrillation 1
• Unstable: Immediate cardioversion
• Stable: IV procainamide or ibutilide 1

Wide-Complex Tachycardia of Uncertain Etiology

• Assume VT until proven otherwise
• Adenosine has increased strength of recommendation for diagnostic purposes in wide-QRS tachycardias 2
• Avoid AV nodal blockers unless SVT with aberrancy confirmed

Documentation Requirements

Always obtain 12-lead ECG during tachycardia and continuous rhythm strip during adenosine administration and at termination 5—essential for diagnosis and guiding definitive therapy.